Estimating the Returns to United Kingdom Publicly Funded Musculoskeletal Disease Research in Terms of Net Value of Improved Health Outcomes
16 Billion Pounds Health Benefit
SOURCE
https://pubmed.ncbi.nlm.nih.gov/29316935/
REFERENCE
127
NICE
REFERENCE
123
organisation
Health Research Policy and Systems
TITLE
Estimating the Returns to United Kingdom Publicly Funded Musculoskeletal Disease Research in Terms of Net Value of Improved Health Outcomes
16 Billion Pounds Health Benefit
SOURCE
https://pubmed.ncbi.nlm.nih.gov/29316935/
DISC COMMENTARY
This economic analysis set out to calculate the real financial return on UK public and charitable funding for musculoskeletal disease research, tracing that funding through to the actual health improvements it eventually produced for patients over several decades.
What was studied?
The study examined 3.5 billion pounds of research funding between 1970 and 2013, measuring the resulting quality-adjusted life years and health benefit generated, and comparing this rate of return against other major disease areas.
What did they find?
The investment generated 871,000 quality-adjusted life years and 16 billion pounds in net health benefit, with UK research responsible for around 30 percent of that. It took roughly 16 years on average between investment and results reaching patients, with a 7 percent annual return.
Why it matters
This shows that funding musculoskeletal research, including research underpinning treatments like those used in chiropractic care, has a genuinely strong and measurable return, comparable to funding for cancer and cardiovascular disease research.
Why we included it
It illustrates why well-funded research matters as a category, not just for one condition: sustained investment in evidence generation reliably translates into measurable gains in real patient outcomes over time.
Help us improve your experience (and hopefully your back).
We use cookies to improve the website and show relevant content to people interested in our services.
We use cookies to help you navigate efficiently and perform certain functions. You can choose which categories to allow below. Cookies categorised as Necessary are always active.
We also use third-party cookies for analytics and advertising. These are only stored with your consent. You can update or withdraw consent at any time via the cookie icon at the bottom-left. This site operates under UK GDPR, the Data Protection Act 2018, and the Privacy and Electronic Communications Regulations (PECR). Cookie Policy • Privacy Policy
Always Active
Necessary cookies are required for core site features including security, network management, and consent storage.
Cookie
Duration
Description
hmdg_cookie_consent
180 days
Stores your cookie consent preferences.
PHPSESSID
Session
WordPress session identifier.
wordpress_logged_in_*
Session
WordPress login authentication.
Functional cookies enable enhanced features such as live chat and remembering preferences.
Cookie
Duration
Description
wp-settings-*
1 year
Stores user interface preferences.
Analytics cookies help us understand visitor behaviour. Controls analytics_storage for Google Analytics 4.
Cookie
Duration
Description
_ga
2 years
Google Analytics — distinguishes users.
_ga_*
2 years
Google Analytics 4 — session persistence.
_gid
24 hours
Google Analytics — distinguishes users.
_gat
1 minute
Google Analytics — throttles request rate.
Performance cookies collect aggregate, anonymous data about site performance.
Cookie
Duration
Description
_gat_gtag_*
1 minute
Google Tag Manager — rate throttle.
Marketing cookies track visits to deliver relevant ads. Controls ad_storage, ad_user_data, and ad_personalization.
What was studied?
The study examined 3.5 billion pounds of research funding between 1970 and 2013, measuring the resulting quality-adjusted life years and health benefit generated, and comparing this rate of return against other major disease areas.
What did they find?
The investment generated 871,000 quality-adjusted life years and 16 billion pounds in net health benefit, with UK research responsible for around 30 percent of that. It took roughly 16 years on average between investment and results reaching patients, with a 7 percent annual return.
Why it matters
This shows that funding musculoskeletal research, including research underpinning treatments like those used in chiropractic care, has a genuinely strong and measurable return, comparable to funding for cancer and cardiovascular disease research.
Why we included it
It illustrates why well-funded research matters as a category, not just for one condition: sustained investment in evidence generation reliably translates into measurable gains in real patient outcomes over time.